In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ferring International Center SA

Division of Ferring Pharmaceuticals AS
www.ferring.com

Latest From Ferring International Center SA

Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting

Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.

Research and Development Strategies Infectious Diseases

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.

Deals M & A

TxCell Plans 2016 U.S. Studies In Crohn’s After Addressing Manufacturing Issues

The French cell therapy company is planning to extend its pivotal Phase II study in Crohn’s disease to the U.S. It is one of the larger studies of a cell therapy to date, evaluating what is thought to be the only cell therapy using regulatory T-lymphocytes.

BioPharmaceutical Europe

Deals Shaping The Medical Industry, May 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March through April 2014

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Ferring Pharmaceuticals AS
  • Senior Management
  • Contact Info
  • Ferring International Center SA
    Phone: (41) (0)58 301 00 00
    Ch. de la Vergognausaz 50
    Vergognausaz 50
    Saint-Prex, 1162
    Switzerland
UsernamePublicRestriction

Register